Related Experiment Videos
Anaphylatoxin C3a peptide contracts human pulmonary vasculature
R R Schellenberg1, J B Mullen, A Foster
1University of British Columbia Pulmonary Research Laboratory, St. Pauls Hospital, Vancouver, Canada.
Pulmonary Pharmacology
|January 1, 1988
Summary
The complement anaphylatoxin C3a C-terminus octapeptide (C3apep) contracts pulmonary arteries and veins by producing thromboxane A2 and leukotrienes. This peptide
Area of Science:
- Immunology
- Pharmacology
- Physiology
Background:
- The complement system plays a role in inflammation and immune responses.
- Anaphylatoxins, such as C3a, are potent mediators derived from complement activation.
- Pulmonary vasculature is a key site for inflammatory mediator action.
Purpose of the Study:
- To investigate the contractile effects of the C3a C-terminus octapeptide (C3apep) on human pulmonary arteries (PA) and veins (PV).
- To elucidate the mechanisms underlying C3apep-induced contractions, including the involvement of pro-inflammatory mediators.
Main Methods:
- Dose-response contractile studies on isolated human PA and PV segments.
- Pharmacological inhibition using cyclooxygenase and lipoxygenase pathway inhibitors.
- Measurement of leukotriene C4 generation following C3apep challenge.
Main Results:
- C3apep induced dose-dependent contractions in both PA and PV, with greater maximal activity in PV.
- Contractions comprised early (thromboxane-dependent) and sustained (leukotriene-dependent) components.
- C3apep challenge led to the generation of leukotriene C4 in both vessels.
Conclusions:
- C3apep elicits significant contractile responses in human pulmonary vasculature.
- These contractions are mediated by the production of thromboxane A2 and leukotrienes.
- The findings highlight a potential role for complement-derived peptides in pulmonary vascular regulation and inflammation.